Beginning in late July 2026, significant new tariffs are expected on imported patented drugs and key ingredients under Section 232 of the Trade Expansion Act. These tariffs – up to 100% for some manufacturers – are intended to drive U.S. drug manufacturing and push companies toward Most‑Favored‑Nation (MFN) pricing agreements. Companies that move quickly with approved onshoring plans and MFN commitments may see reduced or zero tariffs, while those that wait could face steep cost increases and near‑term pricing pressure for U.S. payors and patients.
This is an assertive industrial and pricing strategy aimed at branded drugs. It uses tariffs to drive domestic manufacturing, Most‑Favored‑Nation pricing, and stronger supply chain resilience – but if agreements stall, U.S. healthcare stakeholders could feel near‑term pricing pressure.
Market dynamics are shifting quickly. At ProAct, we continuously evaluate alternative savings strategies to help our clients manage volatility and protect long‑term affordability.
